Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development
Antisense Therapeutics Ltd
Biogen Inc
C4X Discovery Holdings PLC
Daiichi Sankyo Co Ltd
EA Pharma Co Ltd
Immunwork Inc
Morphic Therapeutic Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles
AJM-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATL-1102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXR-159 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ET-3764 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
talizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN-943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ITGA4 and ITGB7 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha 4 and Beta 2 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TE-5232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones
Featured News & Press Releases
Mar 11, 2019: Takeda’s Entyvio achieves superior remission than Humira in ulcerative colitis
Mar 11, 2019: Takeda Cada announces positive results for ENTYVIO (vedolizumab) vs. Humira (adalimumab) in first IBD study to compare biological agents head-to-head
Jan 29, 2019: Perrigo To Receive Milestone Payment Of $250 Million From RPI Fince Trust
Jan 18, 2019: Antisense Therapeutics provides phase II clinical trial in duchenne muscular dystrophy
Jan 07, 2019: RM LAW announces class action lawsuit against Perrigo Company
Jan 03, 2019: First Patient enrolled in Biogens phase 3b Study to evaluate Extended Interval Dosing (EID) with talizumab in Multiple Sclerosis
Dec 17, 2018: Entyvio post-marketing safety data consistent with previous clinical trials
Dec 13, 2018: Protagonist Therapeutics initiates phase 1 trial of oral, gut-restricted, alpha-4-beta-7 integrin antagonist PN-10943
Nov 27, 2018: Protagonist Therapeutics announces new development candidate PN-10943 for the treatment of inflammatory bowel disease
Nov 07, 2018: Takeda announces launch of Entyvio (vedolizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis in Japan
Oct 27, 2018: Takeda comments on ongoing Phase 1 review by the European Commission of the proposed acquisition of Shire
Oct 22, 2018: Investigatiol subcutaneous formulation of Vedolizumab achieves and maintains clinical remission and mucosal healing at Week 52 in patients with moderately to severely active Ulcerative Colitis
Oct 11, 2018: Biogen to present on TYSABRI at 34th Congress of the European Committee for Treatment and Research
Oct 08, 2018: New real-world data alyses support the long-term use of Entyvio (Vedolizumab) in bio-?ve patients for the treatment of moderate to severe ulcerative colitis or crohn’s disease
Oct 02, 2018: Biogen announces presentation on TYSABRI at ECTRIMS 2018
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Antisense Therapeutics Ltd, H1 2019
Pipeline by Biogen Inc, H1 2019
Pipeline by C4X Discovery Holdings PLC, H1 2019
Pipeline by Daiichi Sankyo Co Ltd, H1 2019
Pipeline by EA Pharma Co Ltd, H1 2019
Pipeline by Immunwork Inc, H1 2019
Pipeline by Morphic Therapeutic Inc, H1 2019
Pipeline by Protagonist Therapeutics Inc, H1 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Dormant Products, H1 2019 (Contd..2), H1 2019
Discontinued Products, H1 2019